STIFEL 2026: Compugen has a trial in ovarian cancer for its PVRIG scheduled to read out in the early part of 2027 - later that year brings the start of Astra's big readouts with the TIGIT bispecific

0:00-10:56

CEO Eran Ophir defines what would be a success in the ovarian trial and possible next steps if successful. Plus, TIGIT, Gilead's work on IL18, and looking for new T-cell engager targets.

B-

BiotechTV - News

@biotechtvnews

#pvrigscheduled #astrasbigreadouts #tigitbispecific #lifesciences

The Nile